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Abstract
Introduction: Systemic lupus erythematosus (SLE) 
belongs to a family of related autoimmune rheumatic 
disorders that are capable of affecting multiple organs, and 
they are all associated with a variety of autoantibodies. 
Henoch Schoenlein purpura (HSP) is a sort of systemic 
vasculitis that is not associated with auto-antibodies and 
can affect different organs including the kidneys.   
Case report: A 12 year-old girl presented with 
abdominal pain, low grade fever, swollen and tender 
feet and left hand, skin rash on the lower extremities, 
and high blood pressure. Initial laboratory tests 
revealed severe proteinuria, microscopic hematuria 
and low C3 level. Renal biopsy showed diffuse 
proliferative glomerulonephritis with IgA, fibrinogen 
and C3 deposits. The case was accordingly diagnosed 
as HSP with severe IgA nephropathy. Treatment was 
started with mycophenolate mofetil (MMF) and pulse 
methylprednisolone followed by prednisolone. The 
patient improved and treatment was discontinued after 5.5 
months. One month after withdrawal of her medications, 
the patient presented again with serositis and recurrent 
proteinuria. Both antinuclear antibodies (ANA) and anti 
dsDNA were positive. At this point she was diagnosed 
to have SLE disease and immunosuppressive treatment 
was restarted. Following this, symptoms disappeared, 
proteinuria regressed and anti-dsDNA titer dropped. 
Conclusion: This case presented with features of HSP 
and was later-on diagnosed to have SLE. This kind of 
clinical overlapping has not been reported in the literature 
to the best of our knowledge.
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Introduction
Systemic lupus erythematosus (SLE) belongs to a family 
of related autoimmune rheumatic disorders, including 
dermatomyositis, scleroderma, polymyositis, mixed 
connective tissue disease, and rheumatoid arthritis. All of 
these disorders are capable of affecting multiple organs, 
and they are all associated with a variety of autoantibodies 
that rise and fall depending on the clinical disease pattern 
and/or the treatment given. Because symptoms in systemic 
rheumatic diseases often overlap, the diagnosis of SLE 
is not always clear-cut and true overlapping has been 
frequently reported in the literature. Henoch Schoenlein 
purpura (HSP) is a sort of systemic vasculitis that is not 
associated with auto-antibodies and can affect different 
organs including the kidneys. Its diagnosis is mainly 
clinical. We report on a case that presented with "typical" 
clinical features of Henoch-Schoenlein purpura with 
renal biopsy features of IgA nephropathy. At a later stage 
the full blown features of systemic lupus erythematosus 
became apparent. 
Case report 
A 12 year-old previously healthy girl, was referred to 
our hospital with a history of recent symptoms including 
abdominal pain, low grade fever, swollen and tender 
feet and left hand, skin rash on the lower extremities, 
left-sided neck pain and vomiting. On presentation her 
general condition was stable but her blood pressure was 
138/100 mmHg and her temperature 37.8 C. Her body 
weight was 61 kg and her body surface area (BSA) was 
1.6 m2. On admission she had purpuric, purple-colored 
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skin rash on the lower extremities, no pitting edema, 
no hepatosplenomegaly, no lymphadenopathy or joint 
swelling. Other systems were unremarkable. 
Initial laboratory tests revealed severe proteinuria (6–7 
g/day) and microscopic hematuria (50 RBCs/µl). Serum 
creatinine was  1.0 mg/dl, albumin 24 g/l,  ESR 17 mm/
hour, hemoglobin 10.8 g/dl, Platelets 170,000/µl, WBC 
7500/µl; normal coagulation profile, cholesterol 328 mg/
dl (high), antistreptolysin-O (ASO) titer 400 units, C3 
0.29 g/l (low) and C4  0.16 g/l (lower normal range).
Our primary clinical diagnosis was Henoch-Schoenlein 
purpura (HSP) with significant renal involvement. 
Renal biopsy was performed on the third admission 
day. The examined 29 glomeruli showed diffuse 
increase in the mesangial cells and matrix, accentuation 
of glomerular size and increased lobulation of some 
glomeruli. Immunoflorescent study revealed mesangial 
and membranous granular immunoreactivity to IgA, 
C3 and fibrin, with no immunoreactivity to IgG, IgM or 
C4. The conclusion of the renal histology was a diffuse 
proliferative glomerulonephritis with IgA, fibrinogen 
and C3 deposits.   
According to the clinical presentation, laboratory results 
and histopathology findings, the case was diagnosed 
as HSP with severe glomerulonephritis and nephrotic 
syndrome. This was based on the pathognomonic clinical 
symptoms and signs of HSP, and the fact that 10% of 
HSP cases can have low C3 complement. Moreover, the 
IgA deposits in the renal biopsy and the absence of IgG 
were also supportive of this diagnosis. 
Treatment was started with pulse methylprednisolone at 
a dose of 1g/m2/dose, a total of three doses, followed by 
prednisolone 60 mg/m2/day (max 80 mg/day) for four 
weeks then 40 mg/m2/48 hours for another four weeks 
then tapering. Mycophenolate mofetil (MMF) 750 mg 
twice daily was also started. Additional medications 
included enalapril and candesartan. 
Clinically the purpuric rash lasted two days then started 
to fade out, even before steroids were started. Four weeks 
after starting treatment all clinical complaints resolved 
and C3 and ESR normalized. The proteinuria started to 
decrease slowly but significantly after three months of 
treatment. Four months later the proteinuria dropped to 
0.6 g/day, the RBCs in urine to 20/µl and serum albumin 
increased to 30 g/l. MMF and Prednisolone were given 
for a total treatment time of 5.5 months, and then they 
were tapered-off and discontinued. 
One month after withdrawal of her medications, the 
patient came with chest pain, abdominal pain and mild 
guarding. Echocardiography revealed minimal pericardial 
effusion while abdominal and chest ultrasound showed 
moderate left sided pleural effusion. This was diagnosed 
as serositis. The lab tests revealed a rise in the proteinuria 
to 8 g/day. The other tests were as follows: RBCs in urine 
>100/µl, ESR 36 mm/hour, Albumin 23 g/l, antinuclear 
antibodies (ANA) 3+ positive, anti dsDNA 225 (cut off 
30), and hemoglobin 10.5 g/dl. Serum albumin then 
dropped to 19 g/l.
It was clinically and serologically evident at this point 
that the patient had SLE disease, with 5 out of 11 criteria 
of the American Rheumatism Association (ARA).
Immunosuppressive treatment was restarted using pulse 
methylprednisolone followed by oral prednisolone at 
a dose of 80 mg daily and MMF 750 mg twice daily. 
Hydroxychloroquine was also added. After starting this 
treatment the clinical and biochemical status improved, 
reflected by the disappearance of symptoms and the 
regression of proteinuria as well as normalization of C3, 
C4 and decrease of anti-dsDNA titer. Ten months later 
the laboratory tests showed fairly well controlled SLE 
including 24 hour urine protein of 0.2 g/day, normal C3 
and C4 complement, anti dsDNA 42 IU/ml and ESR 18 
mm/hr. The urine sediment was almost normal.
Discussion
To the best of our knowledge this is the first reported 
case of SLE that clinically presented as HSP with severe 
renal involvement as nephrotic-nephritic syndrome and 
later-on developed clinical and laboratory manifestations 
of SLE with markedly positive serology. Systemic 
lupus erythematosus (SLE) belongs to a family of 
related autoimmune rheumatic disorders, including 
dermatomyositis, scleroderma, polymyositis, mixed 
connective tissue disease, and rheumatoid arthritis. All of 
these disorders are capable of affecting multiple organs, 
and the symptoms in systemic rheumatic diseases often 
overlap as has been repeatedly reported in the literature 
[1-9]. 
In our case, the initial clinical diagnosis of Henoch-
Schoenlein Purpura was clinically confirmed by three 
different skilled pediatricians. The renal histology was a 
diffuse proliferative glomerulonephritis with fibrinogen 
and C3 deposits which can be a feature of either HSP 
or SLE nephritis. However, the positive immunostaining 
for IgA in renal biopsy gave more support to the clinical 
diagnosis of HSP. The low level of complement C3 has 
been described occasionally in HSP cases in the literature 
[10] and deposition of IgA in the kidney are typical 
finding in HSP nephritis [11]. 
The initial clinical and laboratory response after starting 
the intensified immunosuppressive treatment with 
steroids and MMF was first regarded as one of two 
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SLE  that mimicked Henoch-Schoenlein Purpura
possibilities: first, the glomerulonephritis responded 
well to this treatment; second, this could have been a 
spontaneous improvement of HSP nephritis. Because 
data from randomized clinical trials are sparse, there is no 
clear path for treatment recommended for the established 
renal disease in HSP [12, 13].
However, as the patient developed frank clinical and 
laboratory manifestation of SLE after discontinuation 
of this treatment, we retrospectively proposed that this 
could have been a good response of SLE nephritis to 
immunosuppressive therapy [14, 15].
Conclusion
In conclusion, this case presented with clinical features 
of Henoch-Schoenlein purpura and later-on presented 
with findings supporting the diagnosis of systemic lupus 
erythematosus. To the best of our knowledge, this kind of 
clinical overlapping has not been reported in the literature 
so far.
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